News | Ventricular Assist Devices (VAD) | March 08, 2017

Alabama Man Sees Quality of Life Improve After LVAD Surgery

Former firefighter received left ventricular assist device as bridge-to-transplant therapy at University of Alabama at Birmingham

James Ward, LVAD surgery, left ventricular assist device, UAB, University of Alabama at Birmingham

March 8, 2017 —  Congestive heart failure patients at the University of Alabama at Birmingham (UAB) now have reason for optimism with a device that can improve quality of life while waiting for a heart transplant.

A left ventricular assist device (LVAD) is a mechanical heart pump used for patients who have reached end-stage congestive heart failure. Once the LVAD is surgically implanted, the battery-operated, mechanical pump helps the circulating function of the left ventricle — the main pumping chamber of the heart — pump blood to the rest of the body.

“This is amazing, lifesaving technology,” said Salpy Pamboukian, M.D., director of the Mechanical Circulatory Support Device Program at the University of Alabama at Birmingham. “Our patients have excellent quality of life after these procedures.”

LVADs can be used as bridge-to-transplant therapy. This is a lifesaving therapy for patients awaiting a heart transplant. Patients use the LVAD until a heart becomes available. In some cases, the LVAD is able to restore the failing heart, eliminating the need for a transplant.

The LVAD can also be used as a destination therapy: Some patients are not candidates for heart transplants. In this case, patients can receive long-term treatment using an LVAD, which can prolong and improve patients’ lives.

James Ward, of Dothan, Ala., received his LVAD device in 2016 and is a bridge-to-transplant patient. After going through the procedure, he said he has not felt this good for a long time.

“I never thought I could feel this good,” Ward said. “I’m way better than what my normal was.”

Ward, a former firefighter for the city of Dothan for nearly 20 years, was forced to retire after he was diagnosed with congestive heart failure in 2001. While he did not feel like himself for years, the LVAD device he received at UAB has provided him reassurance about his future, which includes spending time with his two children and four grandchildren.

“At some points before I retired, I couldn’t walk from my vehicle to my office,” he said. “Now I can walk. It’s a second chance.”

Patients who receive the LVAD are required to wear a battery and control system pack around the waist. The LVAD pulls blood from the left ventricle into a pump. The pump is placed in the upper part of the abdomen, while another tube attached to the pump is brought out of the abdominal wall to the outside of the body and attached to the pump’s battery and control system.

While it is a lifestyle change, the end result is worth it. Pamboukian said good social support is key to recovery.

“I have to have a caretaker with me most of the time, and I can’t drive; but people need to be aware of these devices because they can save lives, and that’s worth it,” Ward said.

While technology keeps advancing, Pamboukian noted that UAB is the only center in Alabama implanting LVAD devices in patients.

“We encourage patients to research their condition,” she said. “A lot of times, people don’t understand what their options are. Waiting times for heart transplants vary for each person, and people can have excellent lives while they are on this device.”

For more information: www.uab.edu

Related Content

The U.S. Food and Drug Administration (FDA) has granted market clearance for AstraZeneca's dapagliflozin (Farxiga) to reduce the risk of hospitalization for heart failure (HF) in adults with type 2 diabetes (T2D) and established cardiovascular disease (CVD) or multiple cardiovascular (CV) risk factors.
Feature | Heart Failure | October 21, 2019 | Dave Fornell, Editor
October 21, 2019 – The U.S.
Research Shows Drug Can Extend Survival Rates for Heart Failure Patients
News | Heart Failure | October 16, 2019
Researchers have shown for the first time in preclinical studies that the drug Aliskiren can delay the progression of...
The COAPT Economic Analysis sub-study found it is cost effective to treat heart failure patients who have severe secondary mitral regurgitation with MitraClip to reduce their MR symptoms. #TMVR #TCT2019 #TCT19

The COAPT Economic Analysis sub-study found it is cost effective to treat heart failure patients who have severe secondary mitral regurgitation with MitraClip to reduce their MR symptoms.

News | Heart Failure | October 04, 2019
October 4, 2019 – Results of a new economic analysis of the COAPT Trial data found that transcatheter mitral valve re
COAPT Trial three-year data show the MitraClip continued effectiveness in heart failure patients with secondary mitral reguritation. #TCT2019 #TCT19 #mitralclip

COAPT Trial three-year data show the MitraClip continues to show safety and effectiveness in heart failure patients with secondary mitral reguritation.

News | Heart Failure | October 03, 2019
October 3, 2019 – The three-year results from the...
Positive Safety, Efficacy Data Reported on AccuCinch Heart Failure Device
News | Heart Failure | September 27, 2019
Ancora Heart Inc. announced results from an interim analysis of heart failure patients treated in the CorCinch FMR...
Max and Debra Ernst Heart Center Opening at Beaumont Hospital, Royal Oak
News | Heart Failure | September 20, 2019
The new Max and Debra Ernst Heart Center at Beaumont Hospital, Royal Oak, Mich., will open Sept. 30. It is dedicated to...
FDA Grants Fast Track Designation for Farxiga in Heart Failure
News | Heart Failure | September 18, 2019
AstraZeneca announced the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the...
Corvia Medical and physIQ Partner in Global Phase 3 Heart Failure Device Clinical Trial

The REDUCE LAP HF-II study will combine Corvia Medical's InterAtrial Shunt Device (IASD), pictured here, with physIQ's continuous monitoring platform to evaluate the device's efficacy in patients with heart failure. Image courtesy of Corvia Medical.

News | Heart Failure | September 12, 2019
Corvia Medical has sponsored and is actively enrolling patients in a heart failure (HF) device trial that, in addition...
 Tiny Wearable Cameras May Improve Quality of Life in Heart Failure Patients

Image courtesy of Amazon.com

News | Heart Failure | September 11, 2019
The ever-present devices that seem to track all our moves can be annoying, intrusive or worse, but for heart failure...
PARAGON-HF Misses Endpoint in Preserved Heart Failure
News | Heart Failure | September 11, 2019
The angiotensin neprilysin inhibitor sacubitril/valsartan (Entresto) missed its primary endpoint of reducing total...
Overlay Init